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Abstract: Magnetic resonance spectroscopy of biomolecules has recently gained attention for clinical
diagnosis. Its combination with saliva collection and analysis can promote early disease detection and
monitoring, by identifying biomarkers of specific underlying pathology or disease as detected in saliva.
With this novel, non-invasive technique, certain salivary biomarkers have been linked to dental and
periodontal tissues pathology, as well as to specific head and neck cancer malignancies. At present,
diagnostic biomarkers are still in need for further identification (e.g., diagnosis and monitoring of
Sjögren’s syndrome), and nuclear magnetic resonance spectroscopy has been found to be a promising
technique to compliment the current analytic methodology. Moreover, this article reports on the
various data collection and analysis parameters used in the literature. Protocol standardization is yet
to be established not only for the laboratory procedures, but also for the clinical sample collection.
Herein, we review the current status of utilizing nuclear magnetic resonance in order to further
support data on health associated biomarkers, and we also propose a saliva sampling scheduling
protocol with the potential to be used in the clinical and experimental setting for standardization of
the testing methodology.
Keywords: metabolomics; biomarkers; salivaomics; caries; periodontics; oral cancer
1. Introduction—Saliva Testing
A multitude of clinical and laboratory testing is included in the medical sciences, both invasive
and non-invasive. The non-invasive techniques are of paramount importance. They not only eliminate
potential risks to the patient arising from the testing procedure itself, but also eliminate patient
discomfort. The latter increases patient compliance, which is an absolute prerequisite for timely
diagnosis and therapy, as the discomfort of a testing procedure itself often results in avoidance,
and thus diagnosis and treatment delay. The importance of early detection and timely diagnosis
has been greatly emphasized in health sciences, as it has an immediate and substantial effect on the
therapeutic effectiveness and outcome.
Saliva, as the medium for clinical testing, presents unique advantages. The sample collection
is not only non-invasive, but also easy, immediate, and fast without the need for any expensive or
complex instrumentation or advanced training. In addition, it is possible to be repeated multiple
times [1,2]. As a result, it is suitable not only for a one-time testing, but also for continuous monitoring
if deemed medically necessary. Moreover, saliva sampling collection can be easily performed in
various clinical settings, from dental and family medicine clinics to any hospital setting. Because of
its ease and swiftness, it can be performed during routine health appointments, without the need for
additional or specialized appointments. Under established protocols and guidelines, saliva sampling
offers the potential to further become available for non-clinical settings, for distant sites, or even as a
self-sampling at-home kit. This increased accessibility would further promote early timing of detection
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of an underlying condition, even when no symptoms have yet appeared. Consequently, health will be
substantially promoted by reducing the incidence of undiagnosed conditions that lay undetected until
they have progressed to an advanced stage with devastating health results.
Saliva includes information regarding not only the local environment (oral), but also the general
health (systemic conditions). The information is included in organic and inorganic biomarkers.
The specificity and sensitivity of the biomarkers is important in order to be able to distinguish between
physiologic functions and underlying conditions. The biomarkers’ information, as related to health
and disease, can be found and interpreted through proteomics, transcriptomics, microRNAomics,
microbiomics, and metabolomics analysis [2].
Magnetic resonance analysis of saliva has identified significant biomarkers correlated with oral,
dental, and periodontal pathology, as well as salivary biomarkers linked to the presence of head and
neck squamous cell carcinoma and sarcoidosis. Interestingly, salivary biomarkers have been also used
in order to verify and monitor established health after therapy of the pathology [3–15].
2. The Role of Nuclear Magnetic Resonance in Saliva Testing and Analysis
Salivary biomolecules have gained a lot of attention worldwide in the area of proteomics. Salivary
proteome data have been made available to the research community though the Human Salivary
Proteome Wiki (HSPW), a web portal supported by the National Institute of Dental and Craniofacial
Research (NIDCR) of the National Institutes of Health (NIH) [16]. At the moment, the published
HSPW data have been detected through two experimental techniques—mass spectrometry or gel
electrophoresis. Liquid or gas chromatography along with mass spectrometry have been widely used
for proteomic analysis. These techniques are based on the mass-to-charge ratio of the ions in the
sample after separation of the compounds via chromatography [17]. Nuclear magnetic resonance
(NMR) is an alternative and/or complimentary analytical method of great potential for the detection
and analysis of biomarkers that are present in saliva, at the atomic level. Probing and characterization
at the atomic level is of high importance for salivaomics, as it was recently observed that information
in saliva is not only found in locally-produced molecules, but also carried from distant tissues through
nano-vesicles [18]. NMR, as a powerful analytical method, can identify and quantitively analyze
organic acids, amino acids, fatty acids, amines, and alcohol in the provided biofluid sample. Until now,
it has been mainly employed for the analysis of plasma and urine [19].
In general, NMR as local probe exhibits an enhanced site-sensitivity and accuracy in the
characterization of samples in almost all forms (gas, liquid, and solid state). NMR characterization
of biofluids/biomolecules (e.g., saliva, urine, human blood plasma) and biomaterials (e.g., metals,
ceramics, polymers) is a well-established method [20]. There are two principal advantages that
have established NMR spectroscopy (especially solution-state NMR) as one of the most widely used
characterization techniques. These include the small amount of sample needed compared with other
volume average techniques, as well as the swiftness of the experimental data acquisition that can
be performed in as fast as a few minutes [21]. The amount of saliva supernatant used for NMR
analysis ranged from 0.17 to 0.60 mL (Table 1A) [3–15]. A saliva sample does not need any complex
pre-treatment or preparation for the solution state NMR analysis to be performed [17]. Specifically,
the NMR saliva sample preparation consists of centrifugation, and subsequent addition of a NMR
solvent, standard, and buffer to the supernatant inside an NMR tube [3–14]. On the contrary, the more
popular mass spectroscopic analysis requires multiple and more complex sample preparation steps (e.g.,
extraction, purification, digestion, separation), as well as costly labelling reference compounds for data
acquisition and analysis. In this respect, NMR is less time-consuming and more cost-effective for data
acquisition. Notably, the general NMR inherent insensitivity compared with mass spectroscopy can be
improved using multiple scans, cryoprobes, and higher magnetic fields [22,23]. Regarding the current
status of NMR in saliva metabolite analysis, it has been found to be underutilized compared with its
potential, and a standardized protocol needs to be followed for its saliva analysis application [17,19].
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3. NMR Saliva Analysis in Dental Health—Application and Methodology
3.1. Dental Caries
NMR has been found to be able to accurately detect the presence of dental caries in the pediatric
oral cavity, by analyzing the presence and quantity of the corresponding metabolites in the saliva and
comparing it to control samples (non-caries saliva samples). The organic and inorganic metabolites that
are evaluated are based on the Human Metabolome Database. In this study, a 400 MHz Bruker Avance
spectrometer was used with a CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence and T2 filter in order
to suppress signals from other macromolecules, such as proteins (Table 1). On the basis of the NMR
data, caries profile was correlated to increased levels of four metabolites (lactate, fatty acid, acetate,
butyrate, an ambiguous component) and decreased levels of three other metabolites (phenylalanine,
propionate, saccharides) [6]. In a following study, the authors investigated the possibility of evaluating
the efficacy of dental caries treatment via saliva NMR analysis before and after treatment, focusing on
the previously identified metabolites [6], with promising results [5].
In a more recent proton NMR ( 1H-NMR) study, caries profile of children was correlated to
alteration in the expression of 21 saliva metabolites [24]. Regarding the saliva collection methodology,
passive drool was recommended instead of swab applicators for saliva collection, as the latter altered
the NMR metabolomic results. However, no significant difference was found between unstimulated
saliva and stimulated saliva by mastication on paraffin wax pellets for 3–5 min [24]. The avoidance
of swab applicators or substances used as stimulants has been previously recommended in order to
eliminate any alteration of the sample from the applicators and substances used [25].
Interestingly, an attempt was recently made to evaluate the oral health of mothers and their infants
(0–28 months old) during the breastfeeding period via clinical examination accompanied by the saliva
analysis. The NMR spectra presented distinct differences between infants without and with teeth
(older than six months). The latter presented increased levels of multiple metabolites (Table 1B) [4].
3.2. Periodontal Disease
The periodontal disease involves the periodontium, which is specialized soft tissue that surrounds
the teeth and connects them to the underlying bone structure. The disease can be chronic, with bacteria
playing a primary role. It involves inflammation and potential subsequent destruction of the
periodontium and osseous tissues.
NMR clinical studies on salivary profile observed discriminant metabolites that can differentiate
between oral health and chronic generalized periodontitis [11,12], with a reported 91.1% sensitivity,
79.4% specificity, and 84.1% predictive accuracy [12]. Similar observations were reported by recent
1H-NMR metabolome studies that compared saliva samples from controls (oral health) and from two
types of active periodontal disease (chronic and aggressive). NMR on saliva was found to be able
to distinguish with satisfactory predictability between healthy and active disease samples. Hence,
the establishment of a metabolomic profile for periodontal disease is being attempted (Table 1B) [9,10].
However, the metabolic analysis of the patients did not distinguish between the two different types of
periodontal disease [9].
In addition, NMR analysis has been used in order to compare the metabolic changes after
periodontal therapy [7,8]. This shows a great potential for collecting additional information regarding
the effectiveness of current treatment protocols on an individual basis, as well as correlating metabolic
changes during tissue repair. The salivary profile of the patients as measured after the periodontal
therapy was found to be similar to the healthy subjects (Table 1B) [7].
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Table 1. (A) Methodology of nuclear magnetic resonance (NMR) saliva experiments and (B) significant metabolites reported per diagnosis.
(A)
Authors, Year Saliva Collection Method;Quantity Saliva Sample Preparation
Sample Quantity;
NMR Solvent;
Buffer; NMR
Standard (mL)
NMR Buffer
Composition
Post-Mixture
Preparation
NMR Model
(Company)
Temperature of Data
Acquisition (K)
ORAL OR DENTAL PATHOLOGY
da Silva et al., 2019 [4] unstimulated whole saliva, withpipette from floor of the mouth; 0.5 mL
centrifuged (10,000× g for 60 min
at 4 ◦C), stored at −80 ◦C
0.17;
0.019 D2O; N/A;
0.004 DSS
N/A N/A 600 MHz Avance(Bruker) 298
unstimulated whole saliva,
expectoration into sterile plastic tube
on ice; 2 mL
centrifuged (10,000× g for 60 min
at 4 ◦C), stored at −80 ◦C
0.45;
0.05 D2O; N/A;
0.10 DSS
N/A N/A 600 MHz Avance(Bruker) 298
Fidalgo et al., 2014 [5]
morning, unstimulated whole saliva,
with pipette from floor of the mouth,
placed in plastic tube; 1 mL
centrifuged (10,000× g for 60 min
at 4 ◦C), stored at −80 ◦C
0.54;
0.06 D2O; N/A;
0.01 DSS
N/A N/A
400 MHz Avance
DRX (Bruker
Biospin)
298
Fidalgo et al., 2012 [6]
morning, unstimulated whole saliva,
expectoration into plastic tube for
5 min; 3 mL
centrifuged (10,000× g for 60 min
at 4 ◦C), stored at −80 ◦C
0.45;
0.05 D2O; N/A;
0.03 TSP
N/A N/A 400 MHz Avance(Bruker Biospin) 298
Silwood et al., 1999 [3] unstimulated whole saliva, into sterilecontainer for 10 min; N/A
centrifuged (5000× g for 30 min at
4 ◦C), NMR immediately after
0.60;
0.07 D2O; N/A;
TSP
N/A N/A 600 MHz AMX(Bruker) 295
PERIODONTAL PATHOLOGY
Singh et al., 2019 [7]
morning, unstimulated whole saliva
into a sterile container (with 2 mg
NaN3) for 10 min; N/A
immediately frozen at −80 ◦C at
collection, thawed, and
centrifuged (5000× g for 30 min)
0.30;
N/A;
0.30 buffer; N/A
sodium phosphate
buffer 30 s vortexing
800 MHz Avance
III (Bruker
Biospin)
300
Romano et al., 2019 [8]
morning, unstimulated whole saliva
passive drain into sterile tube for
10 min; ~ 1 mL
immediately frozen at −80 ◦C at
collection, thawed, and
centrifuged (5000× g for 30 min at
4 ◦C)
0.30;
N/A;
0.30 buffer; TSP
70 mM Na2HPO4;
20%(v/v) H2O; 6.15
mM NaN3; 6.64 mM
TSP; pH 7.4
N/A 600 MHz (Bruker) 300
Romano et al., 2018 [9]
morning, unstimulated whole saliva
passive drain into sterile tube for
10 min; ~1 mL
immediately frozen at collection,
thawed, and centrifuged (5000× g
for 30 min at 4 ◦C)
0.30;
N/A;
0.30 buffer; TSP
70 mM Na2HPO4;
20%(v/v) H2O; 6.15
mM NaN3; 6.64 mM
TSP; pH 7.4
N/A 600 MHz (BrukerBiospin) 300
Rzeznik et al., 2017 [10] morning, stimulated with paraffin wax;10 mL
stored at −25 ◦C, thawed, and
centrifuged (2000× g for 2 min)
0.60;
0.10 D2O; N/A;
N/A
N/A N/A 500 MHz INOVA(Varian) 298
Garcia-Villaescusa et al.,
2018 [15]
morning, unstimulated whole saliva
passive drain into sterile container;
1.5 mL
immediately frozen at −80 ◦C at
collection
0.45;
D2O;
N/A;
0.04 TSP
N/A N/A 600 MHz AvanceDRX (Bruker) 298
Singh et al., 2017 [11]
morning, unstimulated whole saliva
into a sterile container (with 2 mg
NaN3) for 10 min; N/A
immediately frozen at collection,
thawed, and centrifuged (5000× g
for 30 min at 4 ◦C)
0.30;
N/A;
0.30 buffer; N/A
sodium phosphate
buffer 30 sec vortexing
800 MHz Avance
III (Bruker
Biospin)
300
Aimetti et al., 2011 [12]
morning, unstimulated whole saliva,
non-forceful expectoration into sterile
tube for 10 min; 1 mL
immediately frozen at collection,
thawed, and centrifuged (5000× g
for 30 min at 4 ◦C)
0.30;
N/A;
0.30 buffer; TSP
70 mM Na2HPO4;
20%(v/v) H2O; 6.15
mM NaN3; 6.64 mM
TSP; pH 7.4
30 sec vortexing 600 MHz (BrukerBiospin) 300
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Table 1. Cont.
Authors, Year Saliva Collection Method;Quantity Saliva Sample Preparation
Sample Quantity;
NMR Solvent;
Buffer; NMR
Standard (mL)
NMR Buffer
Composition
Post-Mixture
Preparation
NMR Model
(Company)
Temperature of Data
Acquisition (K)
OTHER CONDITIONS
Mikkonen et al., 2018 [13]
morning, unstimulated whole saliva,
passive drain into sterile glass cup for
5 min; ~5 mL
centrifuged (14,000 rpm for
6 min), stored at −20 ◦C
0.45;
D2O;
0.05 buffer; TSP
1.5 M KH2PO4;
2 mM NaN3; 5.8 mM
TSP; D2O; pH 7.4
centrifuged
10,000× g for 5 min
at 4 ◦C
600 MHz Avance
III HD (Bruker)
sample preheated to
298, 30 min prior
acquisition
Duchemann et al., 2016
[14] stimulated; N/A stored at −20
◦C
0.60;
0.10 D2O; N/A;
N/A
N/A N/A 500 MHz INOVA(Varian) 298
(B)
Authors, Year Diagnosis Univariate Analysis:Increased Metabolites
Univariate Analysis:
Decreased Metabolites
Multivariate Analysis: Increased
Metabolites
Multivariate Analysis: Decreased
Metabolites
ORAL OR DENTAL PATHOLOGY
da Silva et al., 2019 [4]
Breastfeeding infants: Dentate (6
mo+) vs. Edentulous;
Oral Candidiasis, Bohn Nodules
N/A N/A
Dentate vs. Edentulous: lactate, ethanol,
acetate, propionate,
n-butyrate,
n-acetyl sugars
Dentate vs. Edentulous: sugars
Breastfeeding mothers:
Caries; Gingivitis N/A N/A
propionate,
n-butyrate, lactate, ethanol, propionate,
n-acetyl sugar
N/A
Fidalgo et al., 2014 [5] Pediatric Caries vs.3-month-post-tx 1 N/A N/A
Caries vs. Control:
acetate, butyrate, propionate,
fatty acids
3-month-post-tx 1 vs. Caries:
saccharides, acetate, butyrate,
propionate, fatty acids
Fidalgo et al., 2012 [6] Pediatric Caries N/A N/A lactate, fatty acid, acetate, butyrate phenylalanine, propionate, saccharide
Silwood et al., 1999 [3] Root Caries N/A N/A no control/comparison N/A
PERIODONTAL PATHOLOGY
Singh et al., 2019 [7] Chronic Periodontitis vs.post-tx 1 N/A N/A
Perio vs. post-perio sx 2: glutamate,
lactate, succinate, ethane sulfonate,
fucose, proline, ethanol
Control vs. post-perio sx 2: lactate,
ethane sulfonate, ethanol
Perio vs. post-perio sx 2: pyruvate.
Control vs. post-perio sx 2:
alanine, glutamate
Romano et al., 2019 [8]
Generalized Chronic
Periodontitis (GCP) vs.
post-non-surgical tx 1 (GCPtx)
N/A N/A no significance at baseline vs. after tx 1 N/A
Romano et al., 2018 [9]
Generalized Chronic
Periodontitis (GCP); Generalized
Aggressive Periodontitis (GAgP)
N/A N/A
GCP vs. Control: proline, phenylalanine,
isoleucine, valine, tyrosine.
GAgP vs. Control: formate,
phenylalanine, tyrosine.
GCP vs. GAgP: no significant
discrimination
GDP vs. Control: pyruvate,
N-acetyl groups, lactate.
GAgP vs. Control: pyruvate,
N-acetyl-groups, lactate, sarcosine
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Table 1. Cont.
Authors, Year Diagnosis Univariate Analysis:Increased Metabolites
Univariate Analysis:
Decreased Metabolites
Multivariate Analysis: Increased
Metabolites
Multivariate Analysis: Decreased
Metabolites
PERIODONTAL PATHOLOGY
Rzeznik et al., 2017 [10]
Generalized Chronic
Periodontitis (GCP); Generalized
Aggressive Periodontitis (GAgP)
butyrate lactate, GABA
(No significance between GCP and
GAgP) Periodontitis vs. Control:
butyrate
Periodontitis vs. Control: lactate,
methanol, threonine, fucose, acetate,
N-acetyl, GABA, 3Dhydroxybutyrate,
pyruvate, ethanol
Garcia-Villaescusa et al.,
2018 [15] Glioblastoma (GBL); Periodontitis N/A N/A
Periodontitis vs. Control: caproate,
isocaprate + butyrate, isovalerate,
isoleucine,
isopropanol + methanol,
4-aminobutyrate, choline.
GBL vs. Control: propionate, acetate
Periodontitis vs. Control: sucrose,
sucrose+glucose+ lysine,
lactate+proline, lactate, proline. GBL
vs. Control: leucine, valine, isoleucine,
alanine, ethanolamine, sucrose
Singh et al., 2017 [11] Chronic Periodontitis N/A N/A glutamate, valine, succinate, lactate,leucine pyruvate
Aimetti et al., 2011 [12] Generalized ChronicPeriodontitis N/A N/A
acetate,
g-aminobutyrate,
n-butyrate, succinate, trimethylamine,
propionate, valine
pyruvate,
N-acetyl groups
OTHER CONDITIONS
Mikkonen et al., 2018 [13] Head and neck squamous cellcarcinoma
Fucose
(6-deoxy-L-galactose),
1,2-propanediol
proline N/A fucose+ glycine+ methanol+ proline
Duchemann et al., 2016
[14] Sarcoidosis N/A N/A n-butyrate, lactate, acetate methanol
1 tx: treatment, 2 sx: surgery.
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4. NMR Saliva Analysis in Oral Oncology
Early detection in oncology cannot be emphasized enough [26]. Detection and diagnosis of a
malignancy in an early stage significantly improves not only the survival of the patient, but also
the quality of life after the elected therapy [27]. The quality of life should be considered of even
equal significance with survival, as the treatment of a tumor can result in devastating physical and
psychological circumstances for the patient that affects it immensely.
Unfortunately, tumors may lie undetected for a long period of time. The detection depends on the
nature and presentation of symptomatology. It is influenced by various factors, such as the type, stage,
location, and behavior of the tumor. The longer a tumor stays undetected and advances in staging,
the more ‘aggressive’ the treatment modality may be in order for survival and decrease of the rate of
recurrences [28]. Tumor invasion in critical structures, surgical resection of anatomic structures in order
to provide tumor-free healthy margins, irradiation therapy, and/or chemotherapy are all treatment
modalities that increase in severity along with the extent, staging, and behavior of the tumor itself [27].
The available specialized testing, such as computed tomography (CT) scan and magnetic resonance
imaging (MRI) in radiology, may indirectly contribute to detection and treatment delay owing to financial
burden, discomfort, and avoidance by the patient, or even owing to a potential lack of instrumentation
or specialized personnel in rural areas. A safe, cost-effective, comfortable for the patient, universally
accessible testing is needed in order to be possible for it to be performed routinely worldwide. Ideally,
specialized personnel or equipment should not be needed for sample collection. With this directive, saliva
is being investigated as a means of detection and diagnosis for different types of oncologic entities.
For instance, oral squamous cell carcinoma (OSCC), the most common oral cavity malignancy, has
been correlated with the level of expression of certain proteins that can be detected in the saliva [29,30].
Immunohistochemical staining and comparison of resected tumor tissue and non-tumor tissue of the
same patient has been used as a method to further verify an increased level of proposed biomarkers
in the tumor tissues [30]. Of great clinical significance, the use of liquid chromatography/mass
spectroscopy for analysis of salivary metabolites presented 94.6% sensitivity and 84.4% specificity for
the distinction between OSCC and the most frequent oral premalignant lesion known as leukoplakia.
The same technique presented 86.5% sensitivity and 82.4% specificity when OSCC was compared to
controls [31]. In comparison, in a study that used NMR for oral or laryngeal squamous cell carcinoma,
the sensitivity (87.5%) and specificity (93.3%) were higher [13]. NMR has been found to contribute in
the salivary metabolomic analysis and monitoring of sarcoidosis as well (Table 1) [14]. The current
need for further involvement of nanoscale testing techniques in oncologic diagnosis and investigation
is now emphasized, following the contemporary and rapidly evolving literature on biomarkers [32].
5. Proposed Saliva Collection Timing Protocol in the Dental Clinical Setting
Saliva testing begins with collection of the specimen. The saliva collection protocol should
consist of the collection methodology, as well as the timing of initial and subsequent collections for
the monitoring of health and/or pathology. Regarding the saliva collection methodology, certain
recommendations have been proposed in the literature in order to minimize the influence of other
factors and external variants, as well as to increase reproducibility. Saliva collection has been proposed
to be performed 24 h after dental treatment to avoid blood contamination, and 12 h after the use
of alcohol, nicotine, caffeine, or medications (if medically feasible) [9,17]. Morning collection is
widely preferred in order to minimize the effect of the circadian rhythm. At least one hour [4,8,9],
two hours [3–6,10,11,15], or complete refrain upon awaking [12,21] from oral activities, including
eating, drinking, and oral hygiene, was found in the literature (Table 1). Unstimulated whole saliva
with passive expectoration in a sterile container is widely accepted in order to eliminate potential
variants [3–9,11–13,15,25]. When passive expectoration is not feasible, the use of cotton absorbent
materials is not recommended [24,25]. Instead, a pipette has been used to collect the unstimulated
whole saliva from the floor of the mouth for early childhood [4,5].
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The second aspect of the saliva collection procedure is the timing, regarding when and how often
it should be performed. The timing of collection in relation to the health status of an individual would
play a principal role in the early identification of an underlying pathology, but also in the follow-up
monitoring. Here, we propose a saliva sampling schedule template that correlates with routine health
appointments in dental clinics. The biofluid sampling schedule is determined by the individual oral
health assessment, as completed during the clinical appointments (Table 2). In general, follow-up
clinical appointments are determined based on the individual medical assessment, treatment planning,
prognosis, nature of intervention needed (e.g., non-intervention monitoring vs. pharmaceutical
intervention vs. surgical), and so on. For instance, a surgical intervention involving soft and osseous
tissue is often followed by an immediate post-operative appointment to evaluate the initial healing of
soft tissue, and by subsequent appointments at 3–6 months, in accordance with osseous remodeling
rates [8,33]. In our template (Table 2), the clinician would evaluate each oral structure (far left vertical
column) regarding the presence or absence (WNL: within normal limits) of pathological findings.
For instance, the ‘WNL’ circle will be marked for each oral structure with the absence of pathology.
In the case of presence or indication of pathology for an oral structure, the clinician would indicate
the need and the nature of intervention by marking one of the other four columns (non-intervention
monitoring to surgical intervention osseous tissue). The need and nature for intervention increases in
our table from left to right, and the saliva sampling frequency (yellow columns) follows as well. Any
single evaluated structure that needs more ‘invasive’ or more ‘frequent’ monitoring will determine the
final biofluid sampling schedule for the patient. This will be demonstrated on the completed Table 2 by
the furthest to the right marked category of the oral health assessment. The initial biofluid sampling
schedule may be altered as the individual health evaluation is reassessed at follow-up appointments.
We theoretically estimate that during the proposed time intervals, a significant change on saliva
metabolites may occur that would be of interest to investigate, as it may reflect important information
regarding the health status and changes of the oral environment. For instance, saliva profiling at
these follow-up intervals may provide information regarding the physiologic tissue remodeling, tissue
healing versus progressive destruction, pharmaceutical intervention effect and efficiency, stabilization of a
condition after intervention, and thus confirmation or rejection of the selected intervention. However,
it was attempted to make the proposed sample collection regime as versatile and universal as possible.
It needs to be tested experimentally, and modified as needed, in order for clinicians to use it along with
the individualized medical assessment of the patient for early oral health diagnosis and monitoring.
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits.
Oral Health
Assessment: WNL
NO
INTERVENTION
Monitoring
NON-SURGICAL
INTERVENTION
SURGICAL
INTERVENTION
Soft or Dental Tissue
SURGICAL
INTERVENTION
Osseous Tissue
DENTAL
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stabilization of a condition after intervention, and thus confirmation or rejection of the selected 
intervention. However, it was attempted to make the proposed sample collection regime as versatile 
and universal as possible. It needs to be tested experimentally, and modified as needed, in order for 
clinicians to use it along with the individualized medical assessment of the patient for early oral 
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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structure (far left vertical column) regarding th  presence or abse ce (WNL: within normal limits) of 
pathol gical fi dings. For instan e, the ‘WNL’ circle will be m rked for each oral structure with the 
absence of pathol gy. In the case of presence or indication of pathology fo  an oral structure, the 
clinician would indica e the ne d and the ature of intervention by marking one of the other four 
columns (non-intervention monitoring to surgical intervention osseous tissue). Th need and nature 
for intervention increases in our table from left to right, and the saliva sampling frequency (yellow 
columns) follow  as w ll. Any single evaluated structure that needs more ‘invasive’ or more 
‘frequent’ monitoring will determine the final biofluid sampling sch dule for the patient. This will be 
d monstrated on th completed Table 2 by the furthest to the ri ht marked category of the oral health 
assessment. The initial biofluid sa pling schedule may be altered as the individual health evaluation 
is reassessed at follow-up appointments. 
We theoretically estimate that during the propo ed time ntervals, a sig ificant change on saliva 
metabolites may occur that would be of interest to investigate, as it may reflect important information 
regarding the he lth status and cha ges of the oral e vironment. For insta ce, saliva profiling at these 
follow-u  intervals may provide information regarding the physiologic tissue r m deling, tissue 
healing versus progre sive destruction, phar aceutic l in erv tion effe t and efficiency, 
stabilization of a condition after in ervention, and thus confirmation or r j ion of the selected 
intervention. However, it was attempted to make the pr posed sample collection r gime as versatile 
and universal as p ssibl . It n eds to be tested experimentally, and modified as needed, in order for 
clinicians to use it along with the in ividualized medical assessment of the patient for early oral 
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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structure (far l ft vertical column) regarding the p esence or absence (WNL: within normal limits) of 
path logic l findings. For instance, the ‘WNL’ cir le will be marked for eac oral structure with the 
abs ce of pathology. I  the case of presence or indi ation of pathology for an oral structure, the 
clinicia  would indicate he need and the nature of intervention by marking one of the other four 
colum s (non-i t r ti  monito ing o surgical in erve tion osseous tissue). The need and nature 
for interven ion increases in ou  t ble from left to right, and the saliva samp ing frequency (yellow 
columns) follows as we l. Any single valuated structure that ne ds more ‘invasive’ or more 
‘frequent’ monitoring wil determin the fi al biofl id samp ing schedule for the patient. This will be 
demonstrated on he comple ed Table 2 by the furt st to  right marked category of the oral health 
asses m nt. The initial biofl id sampling schedule may be al ered s th  individual health evaluation 
is reassessed at follow-up appointments. 
We the retically estimate that uri g th  propos d time i ervals, a signific nt change on saliva 
metabolites may occur hat w uld b  of interest o investigate, as it may reflect mportant information 
r g rding the health status and changes of the al environment. For instance, saliva profiling at these 
f llow-up int rvals y rovide form tion regarding h physiologic tiss e remodeling, tissue 
heali g versus progress ve d s ruction, ph rmac utical i erve tio  effect and efficiency, 
stab l zation of a conditio fter interv t on, and thus confirmation or rej ction of the selected 
intervention. However, it was attempted t  make the proposed sa ple collection regime as versatile 
and universal as possib e. It eeds to be te ted exper m nt lly, and modified as needed, in order for 
clinicians to use it along with th  individu lized medical assessment of the patient for early oral 
health diagnosis and monitoring. 
Tabl  2. Proposed oral biofluid sa pling schedule. WNL, within normal limits. 
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structure (far left ve tical column) rega ding th  presence or absence (WNL: within normal limits) of 
patholog cal findings. For instanc , the ‘WNL’ circle will be ma ked for each oral structure with the 
absence of pathology. I  the case of presence or indication of pathology for an oral structure, the 
clinician w uld indicate the ne d a d the natur f interve ti n by marking one of the other four 
c lumns (n n-int rve ti n mo itoring t  surgical i terv ntion osseous tissue). The need and nature 
f r intervention inc eases in ur table fr m left to right, a d th  saliva sampling frequency (yellow 
olumns) follows as well. Any single evaluat d t uctur  th t n eds ore ‘invasive’ or more 
‘frequent’ monitoring wi l d termine t  final bioflu d sampling schedule for th patient. This will be 
demonstrated on t  completed Tabl  2 by t e furth st to the ight marked category of the oral health 
assessment. The initial biofluid s mp ing sc dule m y be altered as the individual health evaluation 
is reassessed at follow-up appointments. 
We the r tically es imate that dur ng the propo ed t me intervals, a sign ficant change on saliva 
metabol es may c ur tha would be of inte est o investigate, as it may reflect important information 
regarding the health tatus and changes of he ora  environm nt. F r instance, saliva profiling at these 
follow-up ntervals may p vide inform tion r garding the physio ogic tiss e remodeling, tissue 
he ing versus pr gr ive destru tion, ph rmaceuti al intervention effect and efficiency, 
tab lization of a cond a ter int rvention, and thus confirmation or rejection of the selected 
in ervention. How v r, it was attemp ed to mak the p op sed sa ple collec on regime as versatile 
and universal as possibl . It nee s to be tested experim ntally, an  modifi d as needed, in order for 
li ician  to use it along wi h the ndividualiz d medical ssessment of the patient for early oral 
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampl ng schedule. WNL, within normal limits. 
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structur  far eft vert cal column) rega di g th  presence r absence (WNL: within normal limits) of 
pathologi al find ngs. For instance, the ‘WNL’ ci cle will b ma ked for each oral structure with the 
absence f path l gy. In t e case of pr sence or indication of pathology for an oral structure, the 
clinician would indicate the need and th na ure of interve ti n by marking one of the other four 
c l mns (non-int rve tion mo itoring t  surgical interv ntion osseous tissue). The need and nature 
for intervention inc eas s in ur tab e from left to right, a d th  saliva sampling frequency (yellow 
columns) follows as well. Any single evaluat d tructure th t n eds ore ‘invasive’ or more 
‘ r quent’ mon toring wi l determine the final biofluid sampling schedule for th patient. This will be 
d monstrat on the completed Table 2 by t e furth st to the ight marked category of the oral health 
a s ssm n . The initial biof uid s mpl ng schedule may be altered as the individual health evaluation 
is reassessed at follow-up appointments. 
We theoretically estim te that during the prop ed t me intervals, a sign ficant change on saliva 
m tabolites may ccur th would be of interest to investigate, as it may reflect important information 
regarding the h lt  st tus a d chang  of he ral environment. F r instance, saliva profiling at these 
foll w-up i tervals may p ovide information regarding the physio ogic tiss e remodeling, tissue 
healing versus pr gressi  destru tion, pharma eutical intervention effect and efficiency, 
stabiliz ti  f a ti n after intervention, and thus confirmation or rejection of the selected 
interv ntion. H weve , it was attemp ed to make the prop sed sa ple collec on regime as versatile 
and universal as possibl . It needs to be t sted experimentally, an  modifi d as needed, in order for 
cli ic a s t  use it long with the ndividualiz d medical ssessment of the patient for early oral 
health diagnosis and monitoring. 
Tab  2. Proposed oral bioflu d sampl ng schedule. WNL, within normal limits. 
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structure (far left vertical column) regarding the presence or absence (WNL: within normal limits) of 
pathological findings. For instance, the ‘WNL’ circle will be marked for each oral structure with the 
absence of pathology. In the case of presence or indication of pathology for an oral structure, the 
clinician would indicate the need and the nature of intervention by marking one of the other four 
columns (non-intervention monitoring to surgical intervention osseous tissue). The need and nature 
for intervention increases in our table from left to right, and the saliva sampling frequency (yellow 
columns) follows as well. Any single evaluated structure that needs more ‘invasive’ or more 
‘frequent’ monitoring will determine the final biofluid sampling schedule for the patient. This will be 
demonstrated on the completed Table 2 by the furthest to the right marked category of the oral health 
assessment. The initial biofluid sampling s hedule may be altered as the individual health evaluation 
is reassessed at follow-up appointments. 
We theoretically estimate that during the proposed time intervals, a significant change on saliva 
metabolites may occur that would be of interest to investigate, as it may reflect important information 
regarding the health status and changes of the oral environment. For instance, saliva profiling at these 
follow-up intervals may provide information regarding the physiologic tissue remodeling, tissue 
healing versus progressive destruction, pharmaceutical intervention effect and efficiency, 
stabilization of a condition after intervent on, a d thu  confirmation or rejection f the selec ed 
intervention. Ho ever, it was attempted to make the proposed sample collection regime as versatile 
and universal as possible. It needs to be tested experimentally, and modified as needed, in order for 
clinicians to use it along with the individualized medical assessment of the patient for early oral 
health diagnosis and monitoring. 
Table 2. Proposed ora  biofluid sampling schedule. WNL, within normal limits. 
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structure (far left vertical column) regarding th  presence or abse ce (WNL: within normal limits) of 
pathol gical fi dings. For instan e, the ‘WNL’ circle will be m rked for each oral structure with the 
absence of pathol gy. In the case of presence or indication of pathology fo  an oral structure, the 
clinician would indica e the ne d and the ature of intervention by marking one of the other four 
columns (non-intervention monitoring to surgical intervention osseous tissue). Th need and nature 
for intervention increases in our table from left to right, and the saliva sampling frequency (yellow 
columns) follow  as w ll. Any single evaluated structure that needs more ‘invasive’ or more 
‘frequent’ monitoring will determine the final biofluid sampling sch dule for the patient. This will be 
demonstrated on th completed Table 2 by the furthest to the right marked category of the oral health 
assessm nt. The initial biofluid sa pling sch dule may be altered as the individual health evaluation 
is reassessed at follow-up appointments. 
We theoretically estimate that during the propo ed time ntervals, a sig ificant change on saliva 
metabolites may occur that would be of interest to investigate, as it may reflect important information 
regarding the he lth status and cha ges of the oral e vironment. For insta ce, saliva profiling at these 
follow-u  intervals may provide information regarding the physiologic tissue r modeling, tissue 
healing versus progressive destruction, pharmaceutical in ervention effe t and efficiency, 
stabilization of a condition after in ervention, and thus confirmation or r j io  of the selected 
intervention. However, it was attempted to make the pr posed sample collection r gime as versatile 
and universal as p ssibl . It n eds to be tested experimentally, and modified as needed, in order for 
clinicians to use it along with the in ividualized medical assessment of the patient for early oral 
health diagnosis and monitoring. 
Tab e 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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structure (far l ft vertical column) regarding the p esence or absence (WNL: within normal limits) of 
path logic l findings. For instance, the ‘WNL’ cir le will be marked for eac oral structure with the 
abs ce of pathology. I  the case of presence or indi ation of pathology for an oral structure, the 
clinicia  would indicate he need and the nature of intervention by marking one of the other four 
colum s (non-i t r ti  monito ing o surgical in erve tion osseous tissue). The need and nature 
for interven ion increases in ou  t ble from left to right, and the saliva samp ing frequency (yellow 
columns) follows as we l. Any single valuated structure that ne ds more ‘invasive’ or more 
‘frequent’ monitoring wil determin the fi al biofl id samp ing schedule for the patient. This will be 
demonstrated on he comple ed Table 2 by the furt st to  right marked category of the oral health 
asses m nt. The initial biofl id sampling schedule m y be al er d s th  individual health evaluation 
is reassessed at follow-up appointments. 
We the retically estimate that uri g th  propos d time i ervals, a signific nt change on saliva 
metabolites may occur hat w uld b  of interest o investigate, as it may reflect mportant information 
r g rding the health status and changes of the al environment. For instance, saliva profiling at these 
f llow-up int rvals y rovide formation regarding h physiologic tiss e remodeling, tissue 
heali g versus progress ve des ruction, ph rmac utical intervention effect and efficiency, 
stab l zation of a conditio fter int rv t on, and thus confirmation r rej ction of the selected 
intervention. However, it was attempted t  make the proposed sa ple collection regime as versatile 
and universal as possib e. It eeds to be te ted exper m nt lly, and modified as needed, in order for 
clinicians to use it along with th  individu lized medical assessment of the patient for early oral 
health diagnosis and monitoring. 
Tabl  2. Pr posed oral biofluid sa pling schedule. WNL, within normal limits. 
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structure (far left ve tical column) rega ding th  presence or absence (WNL: within normal limits) of 
patholog cal findings. For instanc , the ‘WNL’ circle will be ma ked for each oral structure with the 
absence of pathology. I  the case of presence or indication of pathology for an oral structure, the 
clinician w uld indicate the ne d a d the natur f interve ti n by marking one of the other four 
c lumns (n n-int rve ti n mo itoring t  surgical i terv ntion osseous tissue). The need and nature 
f r intervention inc eases in ur table fr m left to right, a d th  saliva sampling frequency (yellow 
olumns) follows as well. Any single evaluat d t uctur  th t n eds ore ‘invasive’ or more 
‘frequent’ monitoring wi l d termine t  final bioflu d sampling schedule for th patient. This will be 
demonstrated on t  completed Table 2 by t e furth st to the ight marked category of the oral health 
assessment. The initial biofluid s mp i g sc dule m y be altered as the individual health evaluation 
is reass ssed  follow-up appointments. 
We the r tically es imate that dur ng the propo ed t me intervals, a sign ficant change on saliva 
metabol es may c ur tha would be of inte est o investigate, as it may reflect important information 
regarding the health tatus and changes of he ora  environm nt. F r instance, saliva profiling at these 
follow-up ntervals may p vide information r garding the physio ogic tiss e remodeling, tissue 
he ing versus pr gr ssive destru tion, pharmaceuti al intervention effect and efficiency, 
tab l z tio  of a cond a ter int rvention, and thus confirmation or rejection of the selected 
in ervention. How v r, it was attemp ed to mak the p op sed sa ple collec on regime as versatile 
and universal as possibl . It nee s to be tested experim ntally, an  modifi d as needed, in order for 
li ician  to use it along wi h the ndividualiz d medical ssessment of the patient for early oral 
health diagnosis and monitoring. 
Tabl  2. Proposed oral biofluid sampl ng schedule. WNL, within normal limits. 
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structur  far eft vert cal column) rega di g th  presence r absence (WNL: within normal limits) of 
pathologi al find ngs. For instance, the ‘WNL’ ci cle will b ma ked for each oral structure with the 
absence f path l gy. In t e case of pr sence or indication of pathology for an oral structure, the 
clinician would indicate the need and th na ure of interve ti n by marking one of the other four 
c l mns (non-int rve tion mo itoring t  surgical interv ntion osseous tissue). The need and nature 
for intervention inc eas s in ur tab e from left to right, a d th  saliva sampling frequency (yellow 
columns) follows as well. Any single evaluat d tructure th t n eds ore ‘invasive’ or more 
‘ r quent’ mon toring wi l determine the final biofluid sampling schedule for th patient. This will be 
demonstrat on the completed Table 2 by t e furth st to the ight marked category of the oral health 
a s ssm n . The initial biof uid s mpl ng schedule may be altered as the individual health evaluation 
is reass ssed at follow- p appointments. 
We theoretically estim te that during the prop ed t me intervals, a sign ficant change on saliva 
m tabolites may ccur th would be of interest to investigate, as it may reflect important information 
regarding the h lt  st tus a d chang  of he ral environment. F r instance, saliva profiling at these 
foll w-up intervals may p ovide information regarding the physio ogic tiss e remodeling, tissue 
healing versus pr gressi  destru tion, pharma eutical intervention effect and efficiency, 
stabiliz ti  f a ti n after intervention, and thus confirmation or rejection of the selected 
interv ntion. H weve , it was attemp ed to make the prop sed sa ple collec on regime as versatile 
and universal as possibl . It needs to be t sted experimentally, an  modifi d as needed, in order for 
cli ic a s t  use it long with the ndividualiz d medical ssessment of the patient for early oral 
health diagnosis and monitoring. 
Tab  2. Proposed oral bioflu d sampl ng schedule. WNL, within normal limits. 
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stru ture (far left vertic l column) regarding the prese c  or abse ce (WNL: withi  or l limits) of 
pathological findings. For i stance, the ‘WNL’ ircle will be arked f r each oral structure with t  
abse ce of pathol gy. In the case of presence or i dication of pathology for an oral structur , the 
clinician w uld indicate the need a d th  natur  of int rvention b  marking one of the ther f ur 
columns (non-intervention it ri  to surgical i terv ntio  osseous tissue). Th  e d a d natur  
for interve tion increases in our ta le fr m l ft to right, and th  saliv  sampling fr quency (yellow 
columns) follows as well. Any single evaluated structure that needs more ‘invasive’ or mor  
‘frequent’ monit ring will determine th  final biofluid sampling schedul  for the atient. This will be 
demonstrated on the compl t d Table 2 by t  furthest to the right marked category of the oral health 
assessment. The initi l biofluid sampling sch d le may be altered as th  individu l he lth valu ti  
is reassessed at follow-up appointments. 
W  theoretically estimat  that ring the proposed time i tervals, a significa t chang  on saliv  
metabolites may occur that wo ld be f interest to investigat , as it ay reflect import t inform tion 
regarding the he lth status a d cha g s of the ral envir me t. For instance, s liva pr filing t th se 
follow-up intervals may provide information r garding th  physiologic tissu  r mod ling, tissu  
healing versus progressive destruction, ph rmaceutical int rventio  effect and effici ncy, 
stabilization of a condition after inter ention, and thus confirmation or rejection of t  selected 
interventio . How ver, it was attempted to make the prop sed sample collection regime as v rsatile 
and universal as possible. It needs to be tested experimentally, and modified as needed, in order for 
clinicians to use it along with the indiv u lized medica  asse sment of the p tient f  ea ly oral 
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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stru ture (far l ft vertical column) regardi g t  pr se c  or absence (WNL: wit in ormal limits) f 
pathol gical fi dings. For insta e, the ‘WNL’ ircle will be m rked for ach oral struct re with th  
abs c  of pathol gy. I  th  case of pr senc  or indication of path lo y fo  an oral structur , the 
clinician w uld indica e the ne  a d th  atur  f intervention by marking one of th  other f ur 
columns (non-interventio  monitoring to sur ical interventio  osseous tissue). Th need an  tur  
for intervention incr ases in o r ta l  fro  l ft to right, an  the saliva s mpling frequency (yellow 
columns) follow  s w ll. Any single evaluated structure that needs more ‘i vasive’ or more 
‘frequent’ monit ring will det rmine the fin l biofluid sampling sch dule for the patient. This will be 
demonstrated on th compl t d Tabl  2 by t  furthest to the right marked category of the oral health 
assessment. The initial biofluid sa plin sc dul  may be altered as the individ al ealth evalu ti  
is reassessed at follow-up appointments. 
We theor tically estimate that during the prop d time nt rvals, a sig ificant chan e on saliva 
metabolites may occur that would be of interest to investigat , s it ay r flect i port t information 
regar ing the he lth status a d cha g s of the oral e vir nme t. For i sta ce, saliva profili g at th se 
follow-u  intervals may provide information r garding th  physiol gic tissue r odeling, tissu  
healing versus progressi  destruction, pharmaceutical i r ntion effe t and ffici cy, 
stabilization of a conditio  after in er e tion, and thus confirmation or r j ion of t  s lected 
interventio . Howev r, it was attempted to make the pr pos d sample c llection r gime as versatile 
and univ rsal as p ssibl . It n eds to be tested experimentally, and modified as needed, in order for 
c inicians to use it along with the in iv u liz  med ca as essm nt of the patient for ear y ra  
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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stru tur  (far l ft vertical c lumn) regarding the p se c  or abs nc  (WNL: within ormal limits) of 
path logic l fi dings. F r insta c , the ‘WNL’ ir le will be mark d f r eac oral structure with th  
abs ce of pathology. I  the case of presence or i di atio  f pathology for an oral structur , the 
clinicia  w uld indicate he need a d the natur of interv ntion by marki  on  of the other f r 
colum s (n n-i t r e ti n monito ing o surgical in erve tio  osse us tissue). The need and natur  
for interv ion increases in ou  ta le from l ft to right, and t e saliva samp ing frequency (yellow 
columns) follows as w l. Any single valu te  struct re that n ds more ‘invasive’ or more 
‘frequent’ monit ring wil determine the fi al biofl id samp ing schedule for the patient. This will be 
demonstrated n he compl d Table 2 by t  furt st t   rig t marked category of the oral health 
asses m nt. The initial biofl id s mpling sch dule may be al ered s th  individual h alth evalu ti  
is reassessed at foll w-up appoi tme ts. 
We the retically estimat  that uri g the r posed time i ervals,  sig ific nt change on saliva 
metabolites may occur hat w uld b  of interest o inv stigate, as it may refl ct mport t information 
r g rdi g th he lth status nd cha g s f the al e vironme t. For instance, saliva profili g at these 
f llow-up int rvals y rovid  formation r g rding h physiologic tiss e r odeling, tissu  
heali g v rsus progress ve des ructio , ph rm c utical int rve tion effect and effici ncy, 
stab l zation of a con itio ft r inter t on, a d thus confirmation or rej ction of th  s lected 
interventio . However, it was attempte  t  make t e prop sed sa ple collection regime as versatile 
and universal s possib e. It eeds to be te ted exper m nt lly, and modified as needed, in order for 
clinician  to use it along with th indiv u lized medica assessme t of the patient for early or  
health diagnosis and monitoring. 
Tabl  2. Proposed oral biofluid sa pling schedule. WNL, within normal limits. 
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stru ture (far left ve tical colu n) rega ding the pr se c  or absence (WNL: within normal limits) of 
patholog cal findi gs. F r i sta c , the ‘WNL’ ircle will be ma k  for each oral structure with th  
abs ce f pat ology. I  the c se of presence or indicati n of pathology for an oral structur , the 
clinician w ul  indicate the n d a d th  n tur f interv ti n by marking one of the other f ur 
c lumns (n n-int rve ti n mo itoring t  surgical i terv ntio  osse us tissue). The need and natur  
f r interv ntion inc eases in ur ta le fr m l ft to right, d th  saliva sampling frequency (yellow 
olumns) follows s w ll. Any single evaluate t ctur  t t n ds ore ‘invasive’ or more 
‘frequent’ monit ring wi l d termine t  final bioflu d sampling schedule for th patient. This will be 
d mo strated on t  compl t d Table 2 by t furth st to the ig t marked c tegory of the oral health 
ass ssment. The initial biofluid s mp ing sch dule m y be altered as the individual health evalu ti  
is reassessed t follow-up a pointm nts. 
We theoretically es imate that dur ng t e r po ed t m intervals,  sign ficant change on saliva 
metabol es may c ur tha would be of inte est o inv stigat , as it m y refl ct import t information 
r garding the he lth tatus nd c a ges f he ra  environm t. F r instanc , saliva profiling at these 
follow-up nt rvals may p vide information r g rding th  physio ogic tiss e r modeling, tissu  
he ing v rsus pr gr ssiv  estru tion, pharmac uti al intervention effect and effici ncy, 
tab lization of a cond a ter int r ention, and thus confirmation or rejection of th  selected 
in erventio . How ver, it was attemp e  to mak the p op sed sa ple collec on regime as versatile 
and univers l as possibl . It nee s to be test d exper m ntally, an  modifi d as needed, in order for 
li ician  t  us it along wi h the ndiv u liz d medica  ssessme t of the patient for early or  
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampl ng schedule. WNL, within normal limits. 
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stru t r  far eft rt cal colu n) re a di g th  pres c r absence (WNL: within normal limits) of 
pathologi al find ngs. For instance, the ‘WNL’ i cle will b ma k  for each oral structure with th  
abs c  f path l gy. In t  ase of pr sence or indication of pathology for an oral structur , the 
clinician w uld indicate the need a d th n ur  of interv ti n by marking one of the other f ur 
c l mns (non-int rvention mo itoring t  surgical interv ntio  osseous tissue). The need and natur  
for interventi n i c eas s in ur ta  from l ft t  rig t, a d th  saliva sampling frequency (yellow 
col mns) follows as well. Any single evaluat d tructure t t n ds ore ‘invasive’ or more 
‘ r quent’ mon t ring wi l determine the final biofluid sampling schedule for th patient. This will be 
d monstr t th  complet d Table 2 by t  furth st to the ight marked c tegory of the oral health 
a s ss . Th  initial biof uid s pl ng sch dule may be altered as the individual health evalu ti  
is reassess d t follow-u  appointments. 
We theoretically estim te that during t e prop ed t m  intervals, a sign ficant change on saliva 
m tabolites may ccur th would b  of interest to investigat , as it may reflect import t information 
regarding the lt  st tus a d cha g  f he ral nvironme t. F r instanc , saliva profiling at these 
foll w-u  inter als may p ovide information r garding th  physio ogic tiss e r modeling, tissu  
heali g v rsus pr gressi  destru tion, pharma eutical intervention effect and effici ncy, 
stabili ti  f a ti n after inter ention, and thus confirmation or rejection of th  selected 
interv ntio . H weve , it was attemp ed to make the prop sed sa ple collec on regime as versatile 
and universal as possib . It needs to be t sted experimentally, an  modifi d as needed, in order for 
cli ic a t  use it ong it the ndiv u liz d medica  ssessment of the patient for early oral 
health diagnosis and monitoring. 
Tab  2. Proposed oral bioflu d sampl ng schedule. WNL, within normal limits. 
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stru ture (far left vertic l column) regarding the prese c  or abse ce (WNL: withi  or l limits) of 
pathological findings. For i stance, the ‘WNL’ ircle will be arked f r each oral structure with t  
abse ce of pathol gy. In the case of presence or i dication of pathology for an oral structur , the 
clinician w uld indicate the need a d th  natur  of int rvention b  marking one of the ther f ur 
columns (non-intervention it ri  to surgical i terv ntio  osseous tissue). Th  e d a d natur  
for intervention increases in our ta le fr m l ft to right, and th  saliv  sampling fr quency (yellow 
colum s) follows as well. An  single ev luated structure that needs more ‘invasive’ r mor  
‘frequent’ monit ring will determine th  final biofluid sampling schedul  for the atient. This will be 
demonstrated on the compl t d Table 2 by t  furthest to the right marked category of the oral health 
assessment. The initi l biofluid sampling sch d le may be altered as th  individu l he lth valu ti  
is reassessed at follow-up appointments. 
We theoretically estimate that during the proposed time i tervals, a significa t chang  on saliv  
metabolites may occur that wo ld be f int rest to investigat , as it may reflect imp rt t inform tion 
regarding the he lth status a d cha g s of the r l envir me t. For instance, s liva pr fili g t th se 
follow-up intervals may provide information r garding th  physiologic tissu  r mod ling, tissu  
healing versus progressive destruction, ph rmaceutical int rventio  effect and effici ncy, 
stabilization of a condition after inter ention, and thus confirmation or rejection of t  selected 
interventio . How ver, it was attempted to make the proposed sample collection regime as versatile 
and universal as possible. It needs to be tested experimentally, and modified as needed, in order for 
clinicians to use it along with the indiv u lized medica  asse sment of the p tient f  ea ly oral 
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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stru ture (far l ft vertical column) regardi g t  pr se c  or absence (WNL: wit in ormal limits) f 
pathol gical fi dings. For insta e, the ‘WNL’ ircle will be m rked for ach oral struct re with th  
abs c  of pathol gy. I  th  case of pr senc  or indication of path lo y fo  an oral structur , the 
clinician w uld indica e the ne  a d th  atur  f intervention by marking one of th  other f ur 
columns (non-interventio  monitoring to sur ical interventio  osseous tissue). Th need an  tur  
for intervention incr ases in o r ta le fro  l ft to right, an  the saliva s mpling frequency (yellow 
columns) follow  s w ll. Any single evaluated structure that needs more ‘i vasive’ or more 
‘frequent’ monit ring will det rmine the fin l biofluid sampling sch dule for the patient. This will be 
demonstrated on th compl t d Tabl  2 by t  furthest to the right marked category of the oral health 
assessment. The initial biofluid sa plin sc dul  may be altered as the individ al ealth evalu ti  
is reassessed at follow-up appointments. 
We theoretically estimate that during the prop d time ntervals, a sig ificant chan e on saliva 
metabolites may occur that would be of interest to i vestigat , s it may r flect import t i formation 
egar ing the he lth status a d cha g s of the oral e vir nme t. For i sta ce, saliv  profili g at th se 
follow-u  intervals may provide information r garding th  physiol gic tissue r odeling, tissu  
healing versus progressi  destruction, pharmaceutical i r ntion effe t and ffici cy, 
stabilization of a conditio  after in er e tion, and thus confirmation or r j ion of t  s lected 
interventio . Howev r, it was attempted to make the pr pos d sample c llection r gime as versatile 
and universal as p ssibl . It n eds to be tested experi entally, and modified as needed, in order for 
c inicians to use it along with the in iv u liz  med ca as essm nt of the patient for ear  ra  
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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stru tur  (far l ft vertical c lumn) regarding the p se c  or abs nc  (WNL: within ormal limits) of 
path logic l fi dings. F r insta c , the ‘WNL’ ir le will be mark d f r eac oral structure with th  
abs ce of pathology. I  the case of presence or i di atio  f pathology for an oral structur , the 
clinicia  w uld indicate he need a d the natur of interv ntion by marki  on  of the other f r 
colum s (n n-i t r e ti n monito ing o surgical in erve tio  osse us tissue). The need and natur  
for interv n ion increases in ou  ta le from l ft to right, and t e saliva samp ing frequency (yellow 
columns) foll ws as w l. Any single valu te  struct re that n ds more ‘invasive’ or more 
‘frequent’ monit ring wil determine the fi al biofl id samp ing schedule for the patient. This will be 
demonstrated n he compl d Table 2 by t  furt st t   rig t marked category of the oral health 
asses m nt. The initial biofl id s mpling sch dule may be al ered s th  individual h alth evalu ti  
is reassessed at foll w-up appoi tme ts. 
We the retically estimat  that uri g th  r posed time i ervals,  sig ific nt change on saliva 
m tabolites may occur hat w uld b  of interest o i v tigate, as it m y refl ct mport t information 
r g rdi g th he lth status and cha g s f the al e vironme t. For in tance, saliva profili g at these 
f llow-up int rvals y rovid  formation r g rding h physiologic tiss e r odeling, tissu  
heali g v rsus progress ve des ructio , ph rm c utical int rve tion effect and effici ncy, 
stab l zation of a con itio ft r inter t on, a d thus confirmation or rej ction of th  s lected 
interventio . However, it was attempte  t  make the proposed sa ple collection regime as versatile 
and universal as possib e. It eeds to be te ted exper m nt lly, and modified as needed, in order for 
clinici n  to use it along with th indiv u lized medica assessme t f the patient for early or  
health diagnosis and monitoring. 
Tabl  2. Proposed oral biofluid sa pling schedule. WNL, within normal limits. 
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stru ture (far left ve tical colu n) rega ding the pr se c  or absence (WNL: within normal limits) of 
patholog cal findi gs. F r i sta c , the ‘WNL’ ircle will be ma k  for each oral structure with th  
abs ce f pat ology. I  the c se of presence or indicati n of pathology for an oral structur , the 
clinician w ul  indicate the n d a d th  n tur f interv ti n by marking one of the other f ur 
c lumns (n n-int rve ti n mo itoring t  surgical i terv ntio  osse us tissue). The need and natur  
f r intervention inc eases in ur ta le fr m l ft to right, d th  saliva sampling frequency (yellow 
olumns) follows s w ll. Any ingle evaluate t ctur  t t n ds ore ‘invasive’ or more 
‘frequent’ monit ring wi l d termine t  final bioflu d sampling schedule for th patient. This will be 
d mo strated on t  compl t d Table 2 by t furth st to the ig t marked c tegory of the oral health 
ass ssment. The initial biofluid s mp ing sch dule m y be altered as the individual health evalu ti  
is reassessed t follow-up a pointm nts. 
We theoretically es imate that dur ng t e r po ed t m intervals,  sign ficant change on saliva 
metabol s may c ur tha would be of inte est o inv stigat , as it m y refl ct import t information 
r garding the he lth tatus nd c a ges f he ra  environm t. F r instanc , saliva profiling at these 
follow-up nt rvals may p vide information r g rding th  physio ogic tiss e r modeling, tissu  
he ing v rsus pr gr ssiv  estru tion, pharmac uti al intervention effect and effici ncy, 
tab lization of a cond a ter int r ention, and thus confirmation or rejection of th  selected 
in erventio . How ver, it was attemp e  to mak the p op sed sa ple collec on regime as versatile 
and universal as possibl . It nee s to be tested experim ntally, an  modifi d as needed, in order for 
li ici n   us it along wi h the div u liz d medica  ssessme t of the patient for early or  
health diagnosis and monitoring. 
Table 2. Proposed oral biofluid sampl ng schedule. WNL, within normal limits. 
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stru t r  far eft rt cal colu n) re a di g th  pres c r absence (WNL: within normal limits) of 
pathologi al find ngs. For instance, the ‘WNL’ i cle will b ma k  for each oral structure with th  
abs c  f path l gy. In t  ase of pr sence or indication of pathology for an oral structur , the 
clinician w uld indicate the need a d th n ur  of interv ti n by marking one of the other f ur 
c l mns (non-int rvention mo itoring t  surgical interv ntio  osseous tissue). The need and natur  
for interventi n inc eas s in ur ta  from l ft t  rig t, a d th  saliva sampling frequency (yellow 
col mns) fol ows as well. Any single evaluat d tructure t t n ds ore ‘invasive’ or more 
‘ r quent’ mon t ring wi l determine the final biofluid sampling schedule for th patient. This will be 
d monstr t th  complet d Table 2 by t  furth st to the ight marked c tegory of the oral health 
a s ss . Th  initial biof uid s pl ng sch dule may be altered as the individual health evalu ti  
is reassess d t follow-u  appointments. 
We theoretically estim te that during t e prop ed t m  intervals, a sign ficant change on saliva 
m tabolites may ccur th would b  of interest to investigat , as it may reflect import t information 
regarding the lt  st tus a d cha g  f he ral nvironme t. F r instanc , saliva profiling at these 
foll w-u  inter als may p ovide information r garding th  physio ogic tiss e r modeling, tissu  
heali g v rsus pr gressi  destru tion, pharma eutical intervention effect and effici ncy, 
stabili ti  f a ti n after inter ention, and thus confirmation or rejection of th  selected 
interv ntio . H weve , it was attemp ed to make the prop sed sa ple collec on regime as versatile 
and universal as possibl . It needs to be t sted experimentally, an  modifi d as needed, in order for 
cli ic a t  us  it ng it the ndiv u liz d medica  ssessment of the patient for early oral 
health diagnosis and monitoring. 
Tab  2. Proposed oral bioflu d sampl ng schedule. WNL, within normal limits. 
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stru ture (far left vertic l column) regarding the prese ce or abse ce (WNL: withi  or l limits) of 
pathological findings. For i stance, the ‘WNL’ ircle will be arked f r each oral structure with t e 
abse ce of pathol gy. In the case of presence or i dication of pathology for an oral structur , the 
clinician w uld indicate the need a d th  natur  of int rvention b  marking one of the ther f ur 
columns (non-intervention itori  to surgical i terv ntio  osseous tissue). Th  e d a d natur  
for intervention increases in our ta le fr m left to right, and the saliv  sampling frequency (yellow 
columns) follows as well. Any single evaluated structure that needs more ‘invasive’ or mor  
‘frequent’ monit ring will determin  th  final biofluid sampling schedul  for the atient. This will be 
demonstrated on the compl t d Table 2 by t  furthest to the right marked category of the oral h alth 
assessment. The initi l biofluid sampling sch d le may be altered as th  individu l he lth evaluati  
is reassessed at follow-up appointments. 
We theoretically estimate that during the proposed time i tervals, a significa t chang  on saliv  
metabolites may occur that wo ld be f interest to investigat , as it may reflect import t inform tion 
regarding the he lth status a d cha g s of the ral envir me t. For instance, s liva pr filing t th se 
follow-up intervals may provide information r garding th  physiologic tissu  r mod ling, tissu  
healing versus progressive destruction, ph rmaceutical int rventio  effect and effici ncy, 
stabilization of a condition afte  inter ention, a d t us confirmation or ejection of t  sel cted 
interventio . How ver, it was attempted to make the proposed sample collection regime as versatile 
and universal as possible. It needs to be tested experimentally, and modified as needed, in order for 
clinicians to use it along with the indiv u lized medica  asse sment of the p tient f  ea ly oral 
health diagnosis nd m nitoring. 
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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stru ture (far l ft vertical column) regardi g t  pr se c  or absence (WNL: wit in ormal limits) f 
pathol gical fi dings. For insta e, the ‘WNL’ ircle will be m rked for ach oral struct re with the 
abs c  of pathol gy. I  the case of pr senc  or indication of path lo y fo  an oral structur , the 
clinician w uld indica e the ne  a d th  atur  f intervention by marking one of th  other f ur 
columns (non-interventio  monitoring to sur ical interventio  osseous tissue). Th need an  tur  
for intervention incr ases in o r ta le fro  left to right, an  the saliva s mpling frequency (yellow 
columns) follow  s w ll. Any single evaluated structure that needs more ‘invasive’ or more 
‘frequent’ monit ring will det rmine the fin l biofluid ampling sch dule for the patient. This will be 
demonstrated on th compl t d Tabl  2 by t  furthest to the right marked category of the oral health 
assessment. The initial biofluid sa plin sc dul  may be altered as the individ al ealth evalu ti  
is reassessed at follow-up appointments. 
We theoretically estimate that during the prop ed time ntervals, a sig ificant chan e on saliva 
metabolites may occur that would be of interest to investigat , s it may r flect import t information 
regar ing the he lth status a d cha g s of the oral e vir nme t. For insta ce, saliva profili g at th se 
follow-u  i ervals may provide infor ation r garding th  physiol gic tissue r odeling, tissu  
healing versus progressi  destruction, pharmaceutical i r ntion effe t and ffici cy, 
stabilizati n of  conditio  afte  in er e tion, a d t us confir ation or j ion of t  s lected 
interventio . Howev r, it was attempted to make the pr pos d sample c llection r gime as versatile 
and universal as p ssibl . It n eds to be tested experimentally, and modified as needed, in order for 
c inicians to use it along with the in iv u liz  med ca as essm nt of the patient for ear y ra  
health diagnosis a d monitoring. 
Table 2. Proposed oral biofluid sampling schedule. WNL, within normal limits. 
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stru tur  (far l ft vertical c lumn) regarding the p ese c  or abs nc  (WNL: within ormal limits) of 
path logic l findings. F r insta c , the ‘WNL’ ir le will be mark d f r eac oral structure with the 
abs ce of pathology. I  the case of presence or i di atio  f pathology for an oral structur , the 
clinicia  w uld indicate he need a d the natur of interv ntion by marki  on  of the other f r 
colum s (n n-i t r e ti n monito ing o surgical in erve tio  osse us tissue). The need and natur  
for interven ion increases in ou  ta le from left to right, and t e saliva samp ing frequency (yellow 
columns) follows as w l. Any single valu te  struct re t at n ds more ‘invasive’ or more 
‘frequent’ monit ri  wil determine the fi al biofl id samp ing schedule for the patient. This will be 
demonstrated n he compl ed Table 2 by t  furt st t   right marked category of the oral health 
asses m nt. The initial biofl id s mpling sch dule may be al ered s th  individual h alth evalu ti  
is reassessed at follow-up appoi tme ts. 
We the retically estimate that uri g th  r posed time i ervals, a sig ific nt change on saliva 
metabolites may occur hat w uld b  of interest o i v stigate, as it m y reflect mport t information 
r g rding th he lth status nd cha g s f the al e vironme t. For instance, saliva profili g at these 
f llow-up int rvals m y rovid  fo mation r g rding h physi logic tiss e r odeling, tissu  
heali g v rsus progress ve des ructio , ph rm c utical int rve tion effect and effici ncy, 
stab l zation of a con itio ft  i ter t n, a d t us confi ation or ej ction of th  l cted 
interventio . However, it was attempte  t  make the proposed sa ple collection regime as versatile 
and universal as possib e. It eeds to be te ted exper m nt lly, and modified as needed, in order for 
clinician  to use it along with th indiv u lized medica assessme t of the patient for early or  
health diagnosis and monitoring. 
Tabl  2. Proposed oral biofluid sa pling schedule. WNL, within normal limits. 
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stru ture (far left ve tical colu n) rega ding the pr se c  or absence (WNL: within normal limits) of 
patholog cal findi gs. F r insta c , the ‘WNL’ ircle will be ma k  for each oral structure with the 
abs ce f pat ology. I  the c se of presence or indicati n of pathology for an oral structur , the 
clinician w ul  indicate the n d a d th  n tur f interv ti n by marking one of the other f ur 
c lumns (n n-int rve ti n mo itoring t  surgical i terv ntio  osse us tissue). The need and natur  
f r intervention inc eases in ur ta le fr m left to right, d th  saliva sampling frequency (yellow 
olumns) follows s well. Any single evaluate t ctur  t t n ds ore ‘invasive’ or more 
‘frequent’ monit ring wi l d termine t  final bioflu d sampling schedule for th patient. This will be 
d monstrated on t  compl t d Table 2 by t furth st to the ight marked c tegory of the oral health 
ass ssment. The initial biofluid s mp ing sch dule m y be altered as the individual health evalu ti  
is reassessed t follow-up a pointm nts. 
We theor tically es imate that dur ng t e r po ed t m intervals,  sign ficant change on saliva 
metabol es may c ur tha would be of inte est o inv stigat , as it m y refl ct import t information 
r garding the he lth tatus nd cha ges f he ra  environm t. F r instanc , saliva profiling at these 
follow-up nt rvals may p vide information r g rding th  physio ogic tiss e r modeling, tissu  
he ing v rsus pr gr ssiv  estru tion, pharmac uti al intervention effect and effici ncy, 
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6. Future Application on Sjögren’s Syndrome
A particular medical area that urgently calls for further development of the current clinical
testing and evaluation methodology is Sjögren’s syndrome. Sjögren’s syndrome is a complex,
multisystem autoimmune disease, which results in reduced production of saliva (xerostomia) and
tears (xerophtalmia). Its variability in presentation and symptoms imposes a great challenge for early
detection, diagnosis, staging, and evaluation of the effectiveness of treatment. Biomarkers and saliva
sampling have been emphasized for their potential in non-invasive diagnosis. There is still a great need
for further research in order to establish a universal, reliable, non-invasive method with high sensitivity
and specificity for each subgroup of this syndrome [34]. Recently, metabolomics analyses to identify
salivary and lacrimal biomarkers have been attempted using mass spectroscopy with liquid or gas
chromatography [35,36]. To our knowledge, NMR has not yet been employed for further exploration of
the biomarkers’ potential in the diagnosis and monitoring of Sjögren’s syndrome. Future studies could
contribute significantly to the understanding, early intervention, and effective therapy of the syndrome.
Moreover, even in the areas of oral and dental pathology, the published data remain limited.
Salivary testing needs to be further explored and standardized in order for its development as a
widely available and established testing for the identification and monitoring of oral conditions.
In addition, its demonstrated potential for testing the effectiveness of a dental or periodontal therapy
will enormously facilitate and guide the dental health care [5,8]. Furthermore, it would be of a great
value to explore the potential of salivary diagnostic testing in areas such as infectious or autoimmune
conditions, endocrinology, nephrology, cardiology, and metabolic conditions.
7. Conclusions and Perspectives
Non-invasiveness is of high significance in the clinical setting as it reduces and/or eliminates the
psychological and the physical stress caused by the testing procedure itself. As a result, not only are
the patients more compliant, and thus the diagnosis and monitoring of a condition are not delayed
owing to fear or avoidance of the procedure, but it also allows frequent evaluation even for individuals
with health conditions that would preclude or complicate any surgical testing procedure. Furthermore,
a testing or analysis procedure that is inexpensive, accessible, and does not necessitate specialized
personnel, as in the case of saliva collection, would allow its use worldwide as a universal and standard
of care clinical protocol. As a result, health would be further promoted, and relapses or compromised
quality of life after treatment would be further reduced because of the early detection and intervention.
NMR presents a great potential to compliment the current research on biomarkers as it can detect
nano-characteristics of isolated molecules in the provided bio-sample. Combined with saliva testing,
early detection and intervention could be greatly promoted.
The standardization of the methodology is of high importance. The significant inter-study variability
has been pointed out regarding saliva sample storage, preparation, and NMR quantification method,
in contrast to the established methodology for other biofluids (e.g., plasma, urine) [19]. For the clinical
application of saliva testing as a diagnostic method, specific sampling collection indications and guidelines
need to be established as well, which should be based on the specific health condition that is under
investigation. Here, we attempt to propose such a clinical protocol based on routine follow-up regimens
for oral health.
To sum up, nuclear magnetic resonance in combination with saliva analysis has provided important
information regarding dental and periodontal health, as well as oncologic pathology of oral tissues.
However, it has not yet been explored up to its potential, and future studies are needed to further
identify salivary biomarkers for early diagnosis of not only oral diseases, but also distant sites.
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